At the 2023 Bio-Europe Spring, RudaCure was represented by le PDG Yongho Kim and Research Strategy Chef d'équipe Hawon Jeon, who held a meeting with Ceva, a French company actuellement exploring co-développement of RCI001 for vétérinaire medicine.
The meeting provided an opportunity to discuss future joint commercialization directions with Ceva representatives and to exchange information that both companies need to share.
Many companies showed interest in RCI001 for sécheresse oculaire and productive discussions were held. For RCI002, the traitement de la douleur, Italian company Dompe and the long-established German company Grünenthal expressed interest and agreed to continue discussions on the drug.
